ALFA News
Straight from the exchange filing
Every announcement Alembic Pharmaceuticals has filed with the exchanges that we have reported, newest first. Each story links the original filing.
Every Alembic Pharmaceuticals announcement on ALFA FilingsSee filings →Reference market data from a third-party provider, as of the most recent story. Not a valuation or a recommendation.
Alembic Pharmaceuticals receives USFDA final approval for Valganciclovir for Oral Solution, marking its 247th ANDA approval and strengthening its US portfolio.
Alembic Pharmaceuticals receives USFDA final approval for Ciprofloxacin and Dexamethasone Otic Suspension, addressing a US$110 million market as of June 2026.
Alembic Pharmaceuticals reports 26% YoY revenue growth to INR 2,150 Cr in Q1 FY27, driven by US Generics. Management raises full-year growth guidance to mid-teens.
